Theravance Biopharma, Inc. (TBPH) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, good afternoon. I'd like to welcome everyone to the Theravance Biopharma fourth quarter and full year 2024 conference call. During the presentation, all participants will be in a listen-only mode. A question and answer session will follow the company's formal remarks. To ask a question, press star 1-1 on your phone. Again, that's star 1-1 to ask a question. If listening via webcast, please mute audio on your webcast device before asking a question over the phone. I will repeat these instructions after management completes their prepared remarks. Also, today's conference call is being recorded. And now I'd like to turn the call over to Rick Winningham, Chief Executive Officer. Please go ahead, sir. Yeah, good afternoon, and welcome to Theravance Biopharma's fourth quarter 2024 Earnings Results Conference Call. On slide two, you'll find our forward-looking statements disclaimer, which covers certain risk factors, which could cause actual results to differ materially from any forward-looking statements we might make in today's call, and which are further described in our filings with the SEC. Moving to slide three, I'm joined today by Rhonda Farnham, Chief Business Officer, Anya Miller, Head of Development, and Aziz Swaf, Chief Financial Officer. On slide four, I'll begin by highlighting our fourth quarter results, which represent a strong close to the year. Fourth quarter upelry net sales increased 10% over the fourth quarter of 2023, reaching 66.7 million, an all-time high. And our hospital performance was excellent, with doses up 49% year over year. With Amproloxatine, we achieved solid enrollment in Cyprus throughout the quarter and remain on track with our development timelines. In December, we had a positive exchange with the FDA, which reaff...